Fig 2: miR-140b-5p directly targets CAPN1. (A) Western blot analysis and (B) quantification of CAPN1 in liver tissues following I/R and AML12 cells following H/R. (C) The binding sites between miR-140-5p and 3'UTR of CAPN1. (D and E) Relative luciferase activity in AML12 cells co-transfected with (D) miR-140-5p mimics or (E) inhibitors with WT-CAPN1 or MUT-CAPN1 luciferase reporter vector. (F) Western blot analysis and (G) quantification of CAPN1 in AML12 cells transfected with miR-140-5p mimics and inhibitors. (H) Western blot analysis and (I) quantification of CAPN1 in AML12 cells transfected miR-140-5p mimics/inhibitor and NCs after H/R. (J) Western blot analysis and (K) quantification of CAPN1 in liver tissues after the injection of miR-140-5p agonist. *P<0.05 and **P<0.01 vs. the sham group; %P<0.05 vs. the I/R group; ##P<0.01 vs. the control group; $P<0.01 vs. the mimics NC group; and &P<0.01 vs. the inhibitor NC group. miR, microRNA; CAPN1, calpain 1; I/R, ischemia/reperfusion; H/R, hypoxia/reoxygenation; UTR, untranslated region; WT, wild-type; MUT, mutant; NC, negative control.